Decisions on PARP Inhibitors in Breast Cancer - priME Oncology
prIME Decision Points
prIME Decision Points

Decisions on PARP Inhibitors in Breast Cancer

Clinical Application of a New Treatment Paradigm

Not a member of My prIME? Join now for instant access.

Hear from the experts about the best strategies to improve patient outcomes with PARP inhibitors in breast cancer, including optimizing the continuum-of-care approach and fine tuning systemic therapy. A clinical scenario with patient history, laboratory results, and options for next steps in treatment, along with expert commentary, provide insight for decision making in the care of your patients with breast cancer.

Interactive Presentation

Interactive Presentation



Release Date

Release Date

Nov 19, 2018

Expiration Date

Nov 19, 2019

  • Pierfranco Conte, MDIstituto Oncologico Veneto
    University of Padua
    Padua, Italy
  • Sara Hurvitz, MD, FACPUCLA Jonsson Comprehensive Cancer Center
    University of California, Los Angeles
    Los Angeles, California, United States
  • BRCA Testing in a Patient With Breast Cancer
  • Choice of Neoadjuvant Therapy for a Patient With ER-Positive Breast Cancer and a BRCA1 Mutation
  • Adjuvant Clinical Trial Options for PARP Inhibitors
  • Prophylactic Surgery for a Patient With a BRCA1 Mutation
  • Choice of Therapy for a Patient With Metastatic BRCAm ER-Positive Breast Cancer
  • Choice of Therapy for a Patient With Metastatic BRCAm ER-Positive Breast Cancer Progressing on a CDK4/6 Inhibitor
  • Monitoring and Management of Adverse Events Associated With PARP Inhibitors

This educational activity is specifically designed for oncologists and other healthcare professionals involved in the management of patients with breast cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe the impact of BRCA1/2 testing on clinical outcomes for patients with breast cancer
  • Assess recent and ongoing clinical trial data of PARP inhibitors in patients with breast cancer
  • Select optimal treatment options for patients with BRCA-mutated and “BRCA-like” breast cancer, based on current treatment guidelines and emerging clinical trial data

This educational activity is supported by a grant from AstraZeneca.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Conte has disclosed consulting fees from Celgene. He has also been an independent contractor for Merck Serono, Novartis, and Roche. He was a member of an advisory committee or review panel for Novartis. He has also been speaking and teaching for AstraZeneca, GSK, Novartis, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hurvitz disclosed grants/support from Ambryx, Amgen, Bayer, BI Pharma, Biomarin, Cascadian, Daiichi Sankyo, Dignitana, Genentech, GSK, Lilly, Macrogenics, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, Pieris, Puma, Roche, and Seattle Genetics. She also disclosed fees for travel from Lilly, Novartis, OBI Pharma. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – chair of Inbiomotion Scientific and Clinical Advisory Board; consulting fees for advising on clinical trial protocol development from Amgen, Astellas, and Boehringer Ingelheim; intellectual property rights as co-inventor and patent holder of biomarker under development by Inbiomotion; independent medical education lectures at symposia supported by Amgen, Eisai, and Genomic Health; and travel expenses from Amgen for presentation of clinical trial data at ASCO 2018 conference
  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.